$ARDS

Aridis Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major

PRICE

$1.1 -

Last Close

VOLUME

51,266

DAY RANGE

1.0973 - 1.16

52 WEEK

0.88 - 7.69

Join Discuss about ARDS with like-minded investors

profile
@Baljit123 #StockTraders.NET
recently

ARDS LHF - 2.2 - 2.5 area for me stop over prev hod INDO LHF - if u have shares 6.5 - 7 at open, im not paying for that so just watching

140 Replies 15 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@singletary #StockTraders.NET
recently

$ards let's see what it's got

112 Replies 6 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@singletary #StockTraders.NET
recently

kinda got a liquidity issue on $ards 40m ssr and no volume

79 Replies 11 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@singletary #StockTraders.NET
recently

covered half $ards

85 Replies 12 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@dros #droscrew
recently

$ARDS $19 PT circulating - Bill Gates funding chatter

141 Replies 10 ๐Ÿ‘ 9 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

got no borrows on $ARDS would have hit in pre

101 Replies 8 ๐Ÿ‘ 12 ๐Ÿ”ฅ

profile
@singletary #StockTraders.NET
recently

$lazr $ards so far

142 Replies 10 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@thegiz18 #ivtrades
recently

$ARDS with a pop this morning on a grant from the Gates Foundation to evaluate inhalable monoclonal antibodies

75 Replies 7 ๐Ÿ‘ 6 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

$ARDS is going to be a good one

53 Replies 13 ๐Ÿ‘ 12 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

low float survivor $ARDS

100 Replies 15 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

hopefully $ARDS goes

101 Replies 11 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

add $ards to the monday list

78 Replies 9 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@Baljit123 #StockTraders.NET
recently

IMTE LHF - pump yesterday, its so dead now, ideally we get 5.5 - 6 to scale, but if u want u can start small at 5 but make sure leave room for higher ARDS LHF - dead also, not much meat but 2.5 - 2.8 if it gets there for quickie EFOI LHF - ideally we get 5 - 5.5 to scale BFRI LHF - still meat left so i want 9 - 10 to scale MBOT LHF - same dunno why its still around but 8.5 - 9 to scale stop over 9

54 Replies 11 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@thegiz18 #ivtrades
recently

Added some speculative $ARDS shares back at $2.72 after unloading at $3.38 early on GTC order fill.

74 Replies 11 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@thegiz18 #ivtrades
recently

Nice little premarket pop on $ARDS hit my sell target and took my share position at $3.38. Adding some shares back this morning.

112 Replies 6 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@thegiz18 #ivtrades
recently

Maybe $ARDS can make another run on a break above $3

149 Replies 9 ๐Ÿ‘ 12 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

calling it a day: on watch: $BVXV, $SEAC, $ARDS, $AVCT, $GNFT, $SOFA

81 Replies 13 ๐Ÿ‘ 9 ๐Ÿ”ฅ

BR
@BrittJ #StockTraders.NET
recently

$ARDS Slow grind upwards. watching if it gets over 3

55 Replies 6 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@Baljit123 #StockTraders.NET
recently

RELI LHF - ideally we get 6 - 7 to scale into might start from 5.5 small stop over 7 if holds ARDS LHF - 3.5 - 4 area of interest for me SOPA LHF - still so much meat left 11.5 - 13 area for me stop over 13 if holds

75 Replies 12 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

watch list for tomorrow: short biased: $SOPA, $RELI, $AVCT, $ARDS, $SPRB, $GRTX & $BFRI they are dumping more sharees on the open market so float will be bigger

77 Replies 11 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

If they don't raise on $ARDS today will also be on watch tomorrow

117 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

Wach this: $ARDS: Aridis Pharmaceuticals Shares Up 39%; Hearing Cantor Reiterates Overweight Rating, $18 Price Target

63 Replies 6 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@thegiz18 #ivtrades
recently

$ARDS looks like a pump and dump on the news

42 Replies 12 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@achatzi #ivtrades
recently

@CarlosH the "Low Float " gives me $ARDS, $PTPI, $QNRX are correct ?

55 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@Baljit123 #StockTraders.NET
recently

adjusted plans: BFRI - Not interested in the short bc it has trapped shorts daily ARDS - Looking to short a pop toward 4.60 / 5.00 inn the morning SOPA - Looking to short 12.50 / 13.00 / 13.50 (30%) size OR SHORT WHEN IT GOES RED FOR A NAIL AND BAIL PPSI - Ideally a pop toward 10.00 / 10.50 to short RELI - a short nail and bail at 8.00 might be okay if its NAIL AND BAIL ONLY, but you better stop out if pre mkt HOD breaks out

46 Replies 14 ๐Ÿ‘ 8 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

TTM Watchlist: $ARDS 10 mil float, weaker volumes in pre market. $RELI nano floaterb high volume, On watch for "count the cards" approach, to spot potential float rotation long setups if bases. $PPSI $BFRI Further upside in play. $SOPA multiday runner potential. $GRTX

145 Replies 12 ๐Ÿ‘ 11 ๐Ÿ”ฅ

SO
@soheil.n #StockTraders.NET
recently

$ARDS - lot of resistance on the daily in the 5.5-6 range

101 Replies 9 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@Baljit123 #StockTraders.NET
recently

GRTX - Looking for a morning pop and FAIL to short. Let it do its thing first then I will attack QNRX - Same plan as above. Let it pop toward 3.00 and fail then we will attack. Or if it tanks out of the open will use VWAP as a guide for a nail and bail short ARDS - Looking for a pop toward VWAP / 5.00 / 5.20 to short. This is ETB so must be VERY VERY CAREFUL. Do not over trade it and do not over stay it SOPA - 2 potential trades. Looking to scale in 10% of the time 13.00 / 13.50 / 14.00. Remain 30% size and add only on confirm OR short when it goes red! RELI - HOT CHICK. Let it do its thing. This has SSR so it can trap and zombie. So I am ignoring it for now!!!! CANF - Low hanging fruit. 2.00 / 2.20 lines to short https://myinvestingclub.com/trading/how-to-scale-into-the-watch-list-when-to-use-max-full-size-when-trading-30-rule-watch-list/

105 Replies 11 ๐Ÿ‘ 9 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

In shares $ARDS

119 Replies 15 ๐Ÿ‘ 15 ๐Ÿ”ฅ

profile
@maletone #StockTraders.NET
recently

$ARDS has a ton of dilution above $5

110 Replies 10 ๐Ÿ‘ 11 ๐Ÿ”ฅ

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Friday, July 16, 2021 Futures Up/Down % Last Dow 20.00 0.06% 34,884 S&P 500 3.25 0.09% 4,355 Nasdaq 18.50 0.12% 14,805 U.S. futures are pointing higher, looking to recover following a mixed day on Wall Street Thursday, as investors await the onslaught of quarterly earnings and the potential inflation impact it might be having on businesses while assessing Federal Reserve Chairman Jerome Powellโ€™s repeated assurances that rising price pressures will only be temporary. Just this morning, auto supplier Autoliv ($ALV) posted a quarterly miss on the top and bottom line citing the negative effect of the semiconductor shortage and continued rise in raw material prices. Stocks finished Thursdayโ€™s session mostly lower following comments from Powell that the inflation surge the U.S. is experiencing as it recovers from the pandemic will ease or reverse over time. In Asian markets, The Nikkei Index dropped -276 points to 28,003, the Shanghai Index fell -25 points to 3,539, the Hang Seng Index inched up slightly to 28,004. In Europe, the German DAX is down a few points to 15,620, while the FTSE 100 is up a few points to 7,025. The yield on the benchmark 10-year Treasury rose Friday to 1.33%, trimming its third weekly decline. Busy morning of economic data with retail sales, Michigan confidence data and Business Inventories. Market Closing Prices Yesterday The S&P 500 Index dropped -14.27 points, or 0.33%, to 4,360.03 The Dow Jones Industrial Average rose 53.79 points, or 0.15%, to 34,987.02 The Nasdaq Composite slipped -101.82 points, or 0.70%, to 14,543.13 The Russell 2000 Index declined -12.07 points, or 0.55% to 2,190.29 Events Calendar for Today 8:30 AM ET Retail Sales MoM for June 8:30 AM ET Retail Sales MoM Ex: Autos MoM for June 10:00 AM ET Business Inventories MoM for May 10:00 AM ET University of Michigan Confidence, July-P 1:00 PM ET Baker Hughes Weekly rig count data 4:00 PM ET Net Long-term TIC Flows for May Macro Up/Down Last Nymex 0.28 71.93 Brent 0.21 73.68 Gold -6.35 1,823.15 EUR/USD -0.0007 1.1805 JPY/USD 0.35 110.18 10-Year Note +0.027 1.324% Sector News Breakdown Consumer Autoliv ($ALV) Q2 adj EPS $1.20 vs. est. $1.43; Q2 revs $2.02B vs. est. $2.12B; and cut its full-year outlook, citing the continued impact of the COVID-19 pandemic, the negative effect of the semiconductor shortage and continued rise in raw material prices; lowers year sales growth view to up 20%-22% from prior around 23% Alaska Air ($ALK) sees 2Q ASM -21% vs 2019, sees rev passengers -28% vs 2019, sees load factor 77%, sees 2Q economic fuel cost/gallon $1.90, sees CF from ops about $830Mm American Outdoor Brands Inc. ($AOUT) Q4 adj EPS $0.34 vs. est. $0.23; Q4 revs $64.5M vs. est. $65M; sees year EPS $2.02-$2.26 vs. est. $2.13; sees FY revs $280M-$295M vs. est. $284.9M; Q4 gross margin 44.4%, flat y/y American Airlines ($AAL) tells remaining 3,300 flight attendants on leave theyโ€™ll be coming back by the end of the year, plans to hire 800 to support demand Didi Global ($DIDI) shares fall -6% after China sends state officials from at least seven departments to the ride-hailing giant for cybersecurity review, as regulatory pressure intensifies Energy, Industrials & Materials Alcoa Inc. ($AA) Q2 adj EPS $1.49 vs. est. $1.37; Q2 revs rise 32% to $2.83B vs. est. $2.64B; continues to expect a strong 2021 based on continued economic recovery and increased demand for aluminum in all end markets; its aluminum segment is forecasting double digit growth on year-over-year sales of value-add products in 2021 Marten Transportation ($MRTN) 2Q EPS $0.26 vs est. $0.26 on revs $232.4Mm vs est. $238.6Mm Stevanato Group ($STVN) 32M share IPO priced at $21.00 Dow Inc. ($DOW) downgraded to Underperform from Neutral and LyondellBasell ($LYB) downgraded to Neutral from Buy at Bank America while firm upgraded Olin Corp. ($OLN) to Buy and Westlake Chemical ($WLK) to Neutral in chemical sector Financials Square ($SQ) is forming a new business that pulls together Seller, Cash App & Tidal to focus on โ€œbuilding an open developer platform with the sole goal of making it easy to create non-custodial, permissionless, and decentralized financial services,โ€ CEO Jack Dorsey tweeted State Street ($STT) raises quarterly dividend 10% to 57c from 52c, authorizes $3B share buyback BancFirst ($BANF) Q2 EPS $1.45 vs. est. $1.13; Q2 loan loss provision ($9.9M) vs. $19.3M for 2Q20; Q2 net charge-offs were 0.06% of average loans, compared to none in 2Q20 Peopleโ€™s United Financial ($PBCT) 2Q adj EPS $0.41 vs. est. $0.35; NII $380.9Mm vs. est. $396.4Mm; Net interest margin 2.70% vs. 3.05% y/y; return on average assets 1.07% vs. 0.58% y/y; return on average equity 14.7% vs. 8.10% y/y; net charge-offs ratio 0.1% vs. 0.08% y/y Western Alliance Bancorp ($WAL) Q2 EPS $2.17 vs. est. $1.96; Q2 revs $506.5M vs. est. $494M; Q2 net interest income was $370.5M, an increase of $53.2M from $317.3M I Q1 Bit Digital ($BTBT) files $500M mixed securities shelf Bridge Investment $(BRDG)75M share IPO priced at $16.00 Healthcare Moderna Inc ($MRNA) will join the S&P 500 index as of the start of trading on July 21, replacing Alexion Pharmaceuticals ($ALXN) which is being acquired by AstraZeneca ($AZN) FibroGen ($FGEN) announced that the U.S. FDA Cardiovascular and Renal Drugs Advisory Committee voted to recommend not approving Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase Erasca ($ERAS)5M share IPO priced at $16.00 Imago BioSciences ($IMGO)6M share IPO priced at $16.00 Mesoblast ($MESO) presents clinical outcomes from remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). TScan Therapeutics ($SCAN)67M share IPO priced at $15 Alexion ($ALXN) announces positive topline results from phase 3 study of Ultomiris in adults with generalized myasthenia gravis (gmg); co says study met primary endpoint of change from baseline in the myasthenia gravis-activities of daily living profile total score at week 26 Corvus Pharmaceuticals ($CRVS) discontinues phase 3 study of Mupadolimab (anti-cd73) for covid-19 due to vaccine effectiveness in reducing hospitalizations; reduces projected 2021 net cash used in operating activities by an estimated $11 mln Technology, Media & Telecom Intel ($INTC) is considering a deal to buy GlobalFoundries, The Wall Street Journal reported citing people familiar with the matter, saying a deal may value GlobalFoundries at about $30B https://on.wsj.com/3koWMam Tencent Music ($TME) downgraded to Equal Weight from Overweight at Morgan Stanley Aehr Test Systems ($AEHR) Q4 adj EPS $0.04 vs. est. $0.02; Q4 revs $7.6M vs. est. $7.03M; guides FY revs to $28M AT&T ($T), commenting in a filing, reports prelim 2Q DirecTV churn 1.87% vs 2.42% y/y; DirecTV, AT&T TV and U-Verse TV, prelim 2Q aggregate premium video gross additions 492,000, +2% y/y; DirecTV, AT&T TV and U-Verse TV, prelim 2Q video net losses 473,000, improvement of 47% y/y Blend ($BLND) 20M share IPO priced at $18.00

46 Replies 6 ๐Ÿ‘ 10 ๐Ÿ”ฅ

Key Metrics

Market Cap

19.47 M

Beta

0.61

Avg. Volume

73.64 K

Shares Outstanding

17.70 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgXยฎ technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.

Website:

HQ: ,

Related News